Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzyme replacement royalties, gene-therapy milestone payments, and orphan-drug pricing updates make BioMarin Pharmaceutical’s SEC disclosures uniquely complex. Finding the R&D footnotes that explain trial costs or the revenue breakout for therapies like Voxzogo can take hours.
Stock Titan solves that problem. Our AI reads every BioMarin document on EDGAR—10-Ks, 10-Qs, 8-Ks, S-8s, and especially Form 4 insider filings—and produces plain-English briefs. Use it for BioMarin SEC filings explained simply or to dive deeper with red-line comparisons and keyword search. Whether you need the latest BioMarin quarterly earnings report 10-Q filing or an older BioMarin annual report 10-K simplified, you’ll get both the full PDF and an AI summary that flags pipeline milestones and revenue drivers.
Real-time alerts track BioMarin Form 4 insider transactions real-time, giving you instant visibility into executive stock moves. Curious about compensation? The platform links directly to the BioMarin proxy statement executive compensation section, while our explanations spotlight option grants and performance metrics. For sudden developments, the system pushes notifications with BioMarin 8-K material events explained—from FDA feedback to collaboration agreements—so you never miss market-moving news.
Practical use cases include monitoring BioMarin insider trading Form 4 transactions before trial readouts, comparing quarter-over-quarter R&D spend through our BioMarin earnings report filing analysis, and understanding BioMarin SEC documents with AI when assessing long-term cash burn. All filings update the moment they hit EDGAR, giving analysts, portfolio managers, and biotech enthusiasts a single source for accurate, timely disclosure intelligence.
BioMarin Pharmaceutical Inc. reported Q3 2025 results showing steady sales but a GAAP loss driven by R&D charges. Total revenue was $776.1 million, up from $745.7 million a year ago. Product leaders were VOXZOGO $218.4M, VIMIZIM $182.8M, and PALYNZIQ $108.8M; ALDURAZYME delivered $53.7M and ROCTAVIAN $3.2M.
Operating expenses rose to $822.8 million as R&D reached $409.5M, reflecting a $221.0M acquired in-process R&D charge tied to the Inozyme transaction. The quarter posted a net loss of $30.7M (diluted EPS $(0.16)) versus net income of $106.1M (EPS $0.55) last year. Year‑to‑date, revenue was $2,346.7M with net income $395.5M (diluted EPS $2.04), supported by operating cash flow of $728.4M.
Liquidity remained strong with cash and cash equivalents $1,250.1M, short‑term investments $227.7M, and long‑term investments $512.9M. Total assets were $7.61B. The company has $600.0M of 1.25% convertible notes due 2027. BioMarin completed the Inozyme acquisition (total consideration $329.1M), adding late‑stage enzyme therapy BMN 401; management also plans to pursue options to divest ROCTAVIAN.
BioMarin Pharmaceutical Inc. announced financial results for the third quarter ended September 30, 2025. The company furnished a press release dated October 27, 2025 as Exhibit 99.1.
The press release is furnished and not deemed filed, and the company also included the cover page Inline XBRL data as Exhibit 104.
BioMarin Pharmaceuticals filed an 8-K disclosing its use and definition of Non-GAAP Diluted EPS and related Non-GAAP measures. The filing explains Non-GAAP Diluted EPS as Non-GAAP Income divided by Non-GAAP weighted-average diluted shares outstanding, and defines reconciling adjustments that may exclude amortization of intangible assets, stock-based compensation expense and certain other specified items, plus an estimated tax impact for those adjustments. The company says it uses both GAAP and Non-GAAP results internally to assess operating performance and guide business decisions in its core activities: discovery, development, manufacture, marketing and sale of biologic therapies. The filing cautions that these measures are not prepared under GAAP, have no standardized meaning, and may be calculated differently than similarly named metrics at other companies.
BioMarin Pharmaceutical insider Gregory R. Friberg, listed as Executive Vice President and Chief R&D Officer, reported a sale of 3,304 shares of BioMarin common stock on 09/30/2025 at a price of $54.16 per share. After the transaction, the reporting person beneficially owned 43,506 shares. The Form 4 was signed on 10/02/2025 by an attorney-in-fact.
Viking Global and affiliated funds report a 6.4% common-stock stake in BioMarin Pharmaceuticals (BMRN). Collectively the Reporting Persons beneficially own 12,288,611 shares out of 192,001,650 shares outstanding as of June 30, 2025. Ownership is shared (no reported sole voting or dispositive power); the holdings are held across several Viking entities and funds (largest positions reported: Viking Global Investors LP 12,288,611; Viking Global Performance LLC 8,208,825; Viking Global Equities Master Ltd. 8,044,650; Viking Long Fund Master Ltd. 2,856,671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115). The filing states the securities were not acquired to change or influence control of the issuer. Signatures on the amendment are dated August 14, 2025.
Primecap Management Co/CA filed an amendment to Schedule 13G reporting beneficial ownership of 15,795,383 shares of BioMarin Pharmaceutical Inc. common stock, equal to 8.24% of the class. The filing shows Primecap has sole voting power over 15,087,400 shares and sole dispositive power over 15,795,383 shares. The statement is for CUSIP 09061G101 and designates the security class as common stock. Item 10 certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is dated as an event on 06/30/2025 and signed on 08/13/2025.
BioMarin Pharmaceutical Inc. announced that Erin Burkhart, Group Vice President and Chief Accounting Officer, notified the company of her voluntary resignation effective
BioMarin Pharmaceutical Inc. (BMRN) – Form 4
On 08/01/2025, director Ian T. Clark was awarded 7,000 restricted stock units (RSUs) of BioMarin common stock, recorded with transaction code “A” (acquisition). Because RSUs are granted by the company, the stated price is $0.00 and no open-market cash outlay occurred. Following the grant, Clark’s direct beneficial ownership stands at 7,000 shares; no indirect holdings or derivative positions were reported. The filing contains no sales, options, or additional equity instruments.
The transaction represents routine director equity compensation rather than an opportunistic purchase, but it modestly increases insider alignment with shareholders. No earnings data, guidance changes, or other material corporate events accompany this filing.
Filing: Form S-8 filed by BioMarin Pharmaceutical Inc. (BMRN) on August 5, 2025 to register additional shares under an employee plan.
Key action: The registrant amended the BioMarin 2017 Equity Incentive Plan (as amended April 1, 2025) and registered 8,000,000 additional shares of Common Stock for issuance under the 2017 Plan.
Other facts: The statement incorporates by reference prior S-8 filings (File Nos. 333-218695, 333-234231, 333-262824, 333-275273); exhibits include the Restated Certificate of Incorporation, Amended and Restated Bylaws, legal opinion of Cooley LLP, consent of KPMG LLP, the amended 2017 Plan (Exhibit 99.1), and a filing fee table. The filing is signed by executive officers and directors on August 5, 2025.
FAQ
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
What is the market cap of Biomarin Pharmaceutical (BMRN)?
